
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon, as a leading late-stage contract research organization, demonstrates a robust financial outlook driven by a favorable industry landscape characterized by increased trial outsourcing, consolidation in the pharmaceutical sector, and rising R&D budgets. The successful acquisition of PRA has not only strengthened Icon's portfolio in early-phase and biotech services but also positioned the company to meet or exceed financial targets, showcasing operational efficiency. Additionally, Icon's commitment to gender parity at higher management levels reflects a progressive corporate ethos that can potentially enhance its reputation and attractiveness to clients in a competitive market.
Bears say
The outlook for Icon's stock appears negative due to a reported slower recovery in the biotech sector, with expectations of weakness in the first half of 2025 before any potential growth in the latter half. Additionally, the company's book-to-bill ratio has stagnated, failing to meet prior expectations and suggesting reduced demand for its services in the upcoming quarters. Compounded by a challenging macroeconomic environment affecting customer access to capital, these factors indicate that Icon may face headwinds in achieving projected growth, which could negatively impact its earnings and overall financial performance.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares